Date: March 3rd, 2023

Your Name: Natalia S. Tissera

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

None Fundings			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023

Your Name: Federico Esteso

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NONE	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	NONE	
3	Royalties or licenses	NONE	
4	Consulting fees	VARIFARMA	Personal advisory

5	Payment or honoraria for	BMS	lectures
	lectures, presentations,	ROCHE	lectures
	speakers bureaus,	MERCK	lectures
	manuscript writing or	AMGEN	
	educational events	PFIZER	
		RAFFO SERVIER	
6	Payment for expert	NONE	
0	testimony	NONE	
	testimony		
7	Support for attending meetings and/or travel	VARIFARMA	ASCO 2022
8	Patents planned, issued or	NONE	
	pending		
9	Participation on a Data	NUTRICIA	Advisory Board
	Safety Monitoring Board or		,
	Advisory Board		
10	Leadership or fiduciary role	NONE	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	NONE	
	_		
12	Receipt of equipment,	NONE	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	NONE	
13	financial interests	14014	

I have no conflicts of interest with this	manuscript.		

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023

Your Name: Luca María Romina

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NONE	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	NONE	
3	Royalties or licenses	NONE	
4	Consulting fees	NONE	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	NONE	
	testimony		
7	Support for attending meetings and/or travel	NONE	
8	Patents planned, issued or pending	NONE	
9	Participation on a Data Safety Monitoring Board or Advisory Board	NONE	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NONE	
11	Stock or stock options	NONE	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	NONE	
13	Other financial or non- financial interests	NONE	

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023 Your Name: DIEGO ENRICO

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NONE	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	NONE	
3	Royalties or licenses	NONE	
4	Consulting fees	NONE	

5	Payment or honoraria for	NONE	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	NONE	
	testimony		
7	Support for attending meetings and/or travel	NONE	
8	Patents planned, issued or	NONE	
	pending		
9	Participation on a Data	NONE	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	NONE	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	NONE	
12	Receipt of equipment,	NONE	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	NONE	
	financial interests		

NONE			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023

Your Name: Federico Daniel Waisberg

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NONE	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	NONE	
3	Royalties or licenses	NONE	
4	Consulting fees	NONE	

5	Payment or honoraria for	NONE	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	NONE	
	testimony		
7	Support for attending meetings and/or travel	NONE	
8	Patents planned, issued or	NONE	
	pending		
9	Participation on a Data	NONE	
	Safety Monitoring Board or		
	Advisory Board		
10	10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NONE	
11	Stock or stock options	NONE	
12	Receipt of equipment,	NONE	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	NONE	
	financial interests		

NONE			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023

Your Name: Andrés Rodriguez

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NONE	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	NONE	
3	Royalties or licenses	NONE	
4	Consulting fees	NONE	

5	Payment or honoraria for	NONE	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	NONE	
	testimony		
7	Support for attending meetings and/or travel	NONE	
8	Patents planned, issued or	NONE	
	pending		
9	Participation on a Data	NONE	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	NONE	
	group, paid or unpaid		
11	Stock or stock options	NONE	
	·		
12	Receipt of equipment,	NONE	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	NONE	
	financial interests		

NONE			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023

Your Name: Luisina Inés Bruno

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Roche	Payment to Instituto Alexander Fleming
3	Royalties or licenses	None	
4	Consulting fees	MSD Oncology	

		AstraZeneca
		Merck
		IVICION
5	Payment or honoraria for	Roche
5		
	lectures, presentations, speakers bureaus,	Janssen Oncology
	manuscript writing or	MSD Oncology
	educational events	AstraZeneca
	educational events	AMGEN
		Pfizer
6	Payment for expert	None
	testimony	
7	Support for attending meetings and/or travel	Bayer
		Novartis
		Ellea
		Pfizer
8	Patents planned, issued or pending	None
9	9 Participation on a Data	MSD Oncology
	Safety Monitoring Board or	AstraZeneca
	Advisory Board	Merck
10	Leadership or fiduciary role	None
	in other board, society, committee or advocacy group, paid or unpaid	
11	Stock or stock options	None
	occor or stock options	THE STATE OF THE S
13	Descipt of anyther and	News
12	Receipt of equipment,	None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	None
	financial interests	
	33.5	

Luisina Bruno reports that she has been honoraria of Roche, Janssen Oncology, MSD Oncology, AstraZeneca, AMGEN, and Pfizer. She has been a consultant or advisor for MSD Oncology, AstraZeneca, and Merck. She has been speaker for Roche and Janssen Oncology. She also claims to have received research funding from Roche (payment to Alexander Fleming Institute), travel, accommodation and expenses from Bayer, Novartis, Ellea, and Pfizer.

Please place an "X" next to the following statement to indicate your agreement:							
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.							

Date: March 3rd, 2023

Your Name: MARIANA KUCHARCZYK

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NONE	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	NOBE	
3	Royalties or licenses	NONE	
4	Consulting fees	NONE	

5	Payment or honoraria for	NONE	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	NONE	
	testimony	110112	
	,		
7	Support for attending meetings and/or travel	NONE	
	G ,		
8	Patents planned, issued or	NONE	
	pending		
9	Participation on a Data	NONE	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	NONE	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	NONE	
12	Receipt of equipment,	NONE	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	NONE	
	financial interests		

NONE			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023 Your Name: Mora Amat

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	·		
8	Patents planned, issued or	Nne	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023

Your Name: Ximena B García

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None
5	lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	None
	testimony	
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or	None
	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
12	Receipt of equipment,	None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	None
	financial interests	

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023

Your Name: Maria Teresa Pombo

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
	,		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

one	

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023

Your Name: Ivana Pedraza Salazar

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NONE	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	NONE	
3	Royalties or licenses	NONE	
4	Consulting fees	NONE	

		11010
5	Payment or honoraria for	NONE
	lectures, presentations,	
	speakers bureaus, manuscript writing or	
	educational events	
6	Payment for expert	NONE
	testimony	
	,	
7	Support for attending meetings and/or travel	NONE
	meetings and/or travel	
8	Patents planned, issued or	NONE
	pending	
9	Participation on a Data Safety Monitoring Board or	NONE
	Advisory Board	
10	Leadership or fiduciary role	NONE
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	NONE
12	Receipt of equipment,	NONE
	materials, drugs, medical writing, gifts or other	
	services	
13	Other financial or non-	NONE
	financial interests	

NONE			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023

Your Name: Fernando Sanchez Loria

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NONE	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	NONE	
3	Royalties or licenses	NONE	
4	Consulting fees	NONE	

5	Payment or honoraria for	NONE	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	NONE	
6	Payment for expert	NONE	
	testimony		
7	Support for attending	NONE	
′	meetings and/or travel	NONE	
8	Patents planned, issued or	NONE	
	pending		
9	Participation on a Data	NONE	
	Safety Monitoring Board or		
_	Advisory Board		
10	Leadership or fiduciary role	NONE	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	NONE	
12	Receipt of equipment,	NONE	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	NONE	
	financial interests	_	

NONE			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023

Your Name: Eduardo Huertas

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NONE	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	NONE	
3	Royalties or licenses	NONE	
4	Consulting fees	NONE	

5	Payment or honoraria for	NONE
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	NOVE
6	Payment for expert	NONE
	testimony	
_		NOVE
7	Support for attending	NONE
	meetings and/or travel	
8	Patents planned, issued or	NONE
	pending	
9	Participation on a Data	NONE
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	NONE
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	NONE
12	Receipt of equipment,	NONE
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	NONE
	financial interests	

NONE			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023 Your Name: Mariana Galli

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

NONE			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023

Your Name: Matías Rodrigo Chacón

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	none	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	none	
3	Royalties or licenses	none	
4	Consulting fees	none	

5	Payment or honoraria for	none	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	none	
	testimony		
7	Support for attending meetings and/or travel	none	
8	Patents planned, issued or	none	
	pending		
9	Participation on a Data	none	
	Safety Monitoring Board or		
_	Advisory Board		
10	Leadership or fiduciary role	none	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	none	
	occor or occor operand		
12	Receipt of equipment,	none	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	none	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: March 3rd, 2023

Your Name: Juan Manuel OConnor

Manuscript Title: Atypical pattern of response after neoadjuvant pembrolizumab in MSI-H/dMMR rectal cancer: A Case

Report, Literature Review, and Proposed Management Model

Manuscript number: JGO-22-1140-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	none							
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	none							
3	Royalties or licenses	none							
4	Consulting fees								

5	Payment or honoraria for	none	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	none	
7	Support for attending meetings and/or travel	none	
8	Patents planned, issued or pending	none	
9	Participation on a Data Safety Monitoring Board or Advisory Board	none	
_			
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	none	
11	Stock or stock options	none	
	Stock of Stock options	Hone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	none	
12		Hone	
13	Other financial or non- financial interests	none	

None			

Please place an "X" next to the following statement to indicate your agreement: